护城河对比
最多三家已覆盖的公司，逐项对照。每一项判断都是人工编辑的判断，而非公司披露的数字——并且每一项都附有其引用依据。
| Micron | ASE Technology Holding | Tempus AI | |
|---|---|---|---|
| 护城河评级 | 窄 Micron sits in a three-firm DRAM oligopoly (with Samsung and SK hynix), holds "over 60,000 patents" and leading-edge process technology (industry-first 1-gamma EUV DRAM node in FY2025), yet its FY2025 10-K concedes competitors "may use aggressive pricing" and "may have a larger market share," and consolidated gross margin swung from negative 9% (FY2023) to 40% (FY2025) — a real but commodity-cyclical, non-durable advantage. | 窄 The FY2025 20-F argues ASEH out-competes IDM in-house lines because serving "a large base of customers across a wide range of products" lets it "reduce costs and shorten production cycles through high-capacity utilization and process expertise" and gives its equipment "a longer useful life" — a real but bounded edge, since the same filing calls the global packaging and testing market "highly competitive", notes "most of our customers obtain services from more than one source", flags foundry encroachment ("TSMC has offered advanced packaging technologies such as integrated fan-out"), and warns that "some of our competitors may have superior financial, marketing, manufacturing, research and development and technological resources than we do", offering P.R.C. government support of its domestic semiconductor companies as the example. | 窄 The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| 护城河类型 | 无形资产与知识产权 The 10-K roots Micron's edge in proprietary technology and IP: "over 60,000 patents" granted as of Aug 28, 2025, "significant investments to develop proprietary product and process technology," the industry's first 1-gamma (EUV) DRAM node, ninth-generation G9 NAND, and HBM4 samples to key AI customers. | 成本规模 The advantage the 20-F actually claims is unit economics from volume, not lock-in: specialization and "economies of scale by providing services to a large base of customers", high capacity utilization spreading "relatively high fixed costs", and equipment that lasts longer because of the breadth of the order book. Capital intensity reinforces it — the filing says "semiconductor businesses are capital intensive and require significant investment in expensive equipment manufactured by a limited number of vendors", with the equipment market itself "characterized by intense demand, limited supply, and long delivery cycles". | 网络效应 The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| 领先地位 | 并列领先者 A member of the three-supplier DRAM oligopoly and at the technology frontier (industry-first 1-gamma EUV node), but the smallest of the three by share — the 10-K acknowledges competitors "may have a larger market share" — and a later entrant scaling up in HBM behind SK hynix and Samsung. | 并列领先者 The 20-F calls ASEH "a leading provider of semiconductor manufacturing services in assembly and testing" and "a market leader in SiP technologies from design to assembly with high-volume manufacturing", and says it has "established ourselves as a leader through the successful introduction of leading-edge advanced packaging solutions, which have played a pivotal role in bringing advanced ASIC and HBM products to the marketplace" — but the hedged "we believe we are among the leaders in such packaging processes and technologies", alongside named consolidating rivals (Jiangsu Changjiang Electronics Technology/STATS ChipPAC, Amkor/J-Devices, Tianshui Huatian Technology/Unisem) and TSMC's InFO, describes shared rather than sole leadership. | 势均力敌 The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| 定价权 | 弱 Memory is a commodity with cyclical ASPs: the 10-K flags "volatility in average selling prices" and competitors' "aggressive pricing" as key risks, and consolidated gross margin swung from -9% (FY2023) to 22% (FY2024) to 40% (FY2025), marking Micron largely as a cyclical price-taker; contract-based, supply-tight HBM is a partial exception. | 弱 The 20-F states the industry has "a general trend toward declining prices for products and services of a given technology over time" and that ASEH's own "average selling prices of our packaging and testing services have experienced sharp declines" under "intense price competition". FY2025 consolidated gross margin was 17.7% (up from 16.3%), and management attributes the gain to "higher packaging and testing revenue mix and higher factory utilization" rather than price; the EMS half earned a 9.2% gross margin on raw-material costs equal to 78.7% of EMS revenue, and the five largest customers supplied 46.5% of 2025 operating revenues. | 弱 Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| 综述 | Micron is one of only three scaled DRAM suppliers (with Samsung and SK hynix) and a leading-edge NAND maker, defended by proprietary product and process technology and more than 60,000 granted patents. In FY2025 it shipped the industry's first 1-gamma (EUV) DRAM production node and sampled HBM4 36GB 12-high to multiple key customers for next-generation AI platforms, evidencing process-technology leadership in AI memory (FY2025 10-K). | ASEH sells turnkey assembly and test at a scale most captive IDM lines cannot match: the 20-F says it is "involved in all stages of the semiconductor manufacturing process except circuit design and wafer fabrication", and leans on Taiwan, "currently the largest center for outsourced semiconductor manufacturing in the world", plus a "strategic alliance with TSMC", to sit next to the foundries its customers already use. The durable part is cost position from utilization, not customer capture — the filing concedes customers multi-source and that foundries are moving into advanced packaging from above. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| 产业链位置 | US-based supplier of the memory tier of the AI stack — DRAM, HBM and NAND; the 10-K notes cloud servers for AI and data-centric workloads "require significantly increasing quantities of DRAM, including HBM," and Micron sampled HBM4 to power next-generation AI platforms. | Back-end contractor to the AI silicon chain: the 20-F ties its FOCoS, FOCoS-Bridge and 2.5D/3D lines to "ASICs and HBM for HPC, networking, server and AI/ML applications" and "AI accelerators for AI training", and warns that a slowdown in AI demand would leave "lower utilization rates for our specialized equipment". | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| 产品（份额 / 壁垒） |
|
|
|
| 长周期投票 | +0.05 权重 0.20 · 群体判断 bullish 编辑先验，未经回测。 | +0.05 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 | -0.01 权重 0.20 · 群体判断 neutral 编辑先验，未经回测。 |